TY  - THES
A1  - Gründahl, Marie
T1  - Inzidenz und assoziierte Letalität invasiver Mykosen bei Patienten mit akuter lymphatischer Leukämie
T1  - Incidence and mortality of invasive fungal diseases in patients with new diagnosed acute lymphoblastic leukemia
N2  - Invasive Mykosen stellen bei Patienten mit hämatologischer Grunderkrankung eine lebensbedrohliche Komplikation dar. Im Rahmen dieser retrospektiven monozentrischen Studie wurde die Inzidenz und Letalität invasiver Mykosen bei erwachsenen Patienten mit einer neu diagnostizierten akuten lymphatischen Leukämie erfasst, sowie die Krankheitsverläufe und der Einfluss einer antimykotischen Prophylaxe analysiert. 
In der untersuchten Kohorte war eine erhöhte Inzidenz invasiver Mykosen feststellbar, ebenso wie eine negative Beeinflussung des Krankheitsverlaufs durch invasive Mykosen. Es konnte kein signifikanter Nutzen einer antimykotischen Prophylaxe verzeichnet werden. 
Eine diagnostisch gesteuerte Therapie der invasiven Mykosen ist anzustreben. Die Frage nach dem Nutzen einer antimykotischen Prophylaxe bleibt auch in dieser Arbeit nicht abschließend geklärt. Eine großangelegte prospektive Studie hierzu wäre wünschenswert. Durch Risiken insbesondere hinsichtlich schwerwiegender Medikamenteninteraktionen scheinen aktuell jedoch retrospektive Daten mit individuell angesetzter Prophylaxe die einzige mögliche Näherung an diese Fragestellung zu sein.
N2  - Invasive mycoses are a life-threatening complication for patients with underlying hematological diseases. In this retrospective monocentric study, incidence and lethality of invasive mycoses in adult patients with newly diagnosed acute lymphoblastic leukemia were recorded. Furthermore, the courses of disease and the effect of antifungal prophylaxis were analyzed.  An increased incidence of invasive mycoses was observed, as well as a negative influence of invasive mycoses on the course of disease. No significant benefit of antimycotic prophylaxis was evident.
To improve the patients’ outcomes, a diagnostic-driven therapy should be pursued. The benefit of antimycotic prophylaxis is not conclusively clarified in this study. A large-scale prospective study on this matter would be advisable. However, especially regarding severe drug interactions, retrospective data with individually applied prophylaxis seems to be the only reasonable approach at this time.
KW  - Mykose
KW  - Lymphatische Leukämie
KW  - Akute Leukämie
KW  - Antimykotikum
KW  - acute lymphoblastic leukemia
KW  - mycosis
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-206434
ER  - 
TY  - JOUR
A1  - Deak, Dalma
A1  - Pop, Cristina
A1  - Zimta, Alina-Andreea
A1  - Jurj, Ancuta
A1  - Ghiaur, Alexandra
A1  - Pasca, Sergiu
A1  - Teodorescu, Patric
A1  - Dascalescu, Angela
A1  - Antohe, Ion
A1  - Ionescu, Bogdan
A1  - Constantinescu, Catalin
A1  - Onaciu, Anca
A1  - Munteanu, Raluca
A1  - Berindan-Neagoe, Ioana
A1  - Petrushev, Bobe
A1  - Turcas, Cristina
A1  - Iluta, Sabina
A1  - Selicean, Cristina
A1  - Zdrenghea, Mihnea
A1  - Tanase, Alina
A1  - Danaila, Catalin
A1  - Colita, Anca
A1  - Colita, Andrei
A1  - Dima, Delia
A1  - Coriu, Daniel
A1  - Einsele, Hermann
A1  - Tomuleasa, Ciprian
T1  - Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia
JF  - Frontiers in Immunology
N2  - Background: Therapy for acute lymphoblastic leukemia (ALL) are currently initially efficient, but even if a high percentage of patients have an initial complete remission (CR), most of them relapse. Recent data shows that immunotherapy with either bispecific T-cell engagers (BiTEs) of chimeric antigen receptor (CAR) T cells can eliminate residual chemotherapy-resistant B-ALL cells.
Objective: The objective of the manuscript is to present improvements in the clinical outcome for chemotherapy-resistant ALL in the real-life setting, by describing Romania's experience with bispecific antibodies for B-cell ALL.
Methods: We present the role of novel therapies for relapsed B-cell ALL, including the drugs under investigation in phase I-III clinical trials, as a potential bridge to transplant. Blinatumomab is presented in a critical review, presenting both the advantages of this drug, as well as its limitations.
Results: Bispecific antibodies are discussed, describing the clinical trials that resulted in its approval by the FDA and EMA. The real-life setting for relapsed B-cell ALL is described and we present the patients treated with blinatumomab in Romania.
Conclusion: In the current manuscript, we present blinatumomab as a therapeutic alternative in the bridge-to-transplant setting for refractory or relapsed ALL, to gain a better understanding of the available therapies and evidence-based data for these patients in 2019.
KW  - blinatumoman
KW  - acute lymphoblastic leukemia
KW  - bridge-to-transplant
KW  - real life setting
KW  - bispecific antobodies
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-193921
SN  - 1664-3224
VL  - 10
IS  - 2856
ER  -